Odyssey Therapeutics, Inc.
ODTX
$19.18
$0.291.51%
NASDAQ
| 03/31/2026 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 1.92M | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 1.92M | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | 1.92M | |||
| SG&A Expenses | 7.35M | 7.95M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 39.67M | 46.73M | |||
| Operating Income | -39.67M | -44.81M | |||
| Income Before Tax | -38.20M | -38.30M | |||
| Income Tax Expenses | 63.00K | 140.00K | |||
| Earnings from Continuing Operations | -38.26M | -38.44M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -38.26M | -38.44M | |||
| EBIT | -39.67M | -44.81M | |||
| EBITDA | -38.50M | -43.51M | |||
| EPS Basic | -6.77 | -39.37 | |||
| Normalized Basic EPS | -4.21 | -28.14 | |||
| EPS Diluted | -6.77 | -39.37 | |||
| Normalized Diluted EPS | -4.21 | -28.14 | |||
| Average Basic Shares Outstanding | 5.66M | 976.10K | |||
| Average Diluted Shares Outstanding | 5.66M | 976.10K | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||